HCPCS Level II code J1720 denotes an injection of hydrocortisone sodium succinate, up to 100 mg, a short-acting corticosteroid frequently used for acute inflammation, allergic reactions, and as part of inpatient and outpatient treatment regimens. Nationally, this code matters because it captures a commonly administered parenteral medication across multiple care settings, affecting outpatient drug billing, inventory management, and payer coverage determinations. Key payers addressed in this summary include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what J1720 represents clinically and operationally, which payers commonly cover the service, and what typical sites of service and service types are associated with the code. The publication also provides benchmarks and policy-relevant context on billing practice, claims processing, and reimbursement considerations for hydrocortisone injections. Where specific data are missing from the input, the text notes that information is not available. The content is intended for a national audience of billing professionals, practice managers, and policy analysts seeking concise, actionable context about the HCPCS Level II code J1720.